Clinigence Holdings (NUTX) AI Stock Analysis

Company Guidance

Management reiterated a constructive outlook: for the first half of 2026 total revenue was $427.2M (down 6.3% y/y) with Q2 revenue $210.8M (down 13.6% y/y), net income attributable rose to $112.6M YTD (a ~3,100% increase from $3.5M) and Q2 net income was $65.8M, adjusted EBITDA was $147.5M YTD (up 2.2%) and $90.0M in Q2 (up 25.7%), hospital visits were 99,704 YTD (up 6.2%) with Q2 hospital visits 49,962 (up 9.6%) and same-hospital growth of 3.4% YTD / 6.3% in Q2, revenue per visit has normalized to roughly $4,000–$4,200 (vs a Q2‑25 spike of $5,185 from catch‑up), the company submits ~50–60% of claims to IDR, prevails on >85% of determinations and collects >80% of wins, and management expects arbitration/contract‑services costs to decline ~25–30% overall (arbitration-specific costs moving to the high teens/low‑20s% of arbitration revenue) after CMS cut the IDR fee from $115 to $15 and a HaloMD amendment that materially reduced costs (roughly $38.4M and $9.6M elements and ~ $4.3M Q2 CMS fee benefit); balance sheet/operating metrics noted: cash ~ $205–207M, net long‑term debt ~$31.1M, accounts receivable $351.7M, net cash from operations $109.7M (up 40%), Q2 gross margin 67% (54.5% YTD), G&A ~7.9% Q2 /7.3% YTD, employee turnover 6.8%, and a continued development cadence of 3–5 new hospitals per year with three openings expected in Q3–Q4 2026.